Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets

Movement Disorders

Volumn 25, Issue 3, 2010, Pages 377-384

  Tayarani Binazir, Kayhan A ^a   Jackson, Michael J ^a   Rose, Sarah ^a   Olanow, C Warren ^b   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Dyskinesia; L dopa; Motor disability; MPTP; Parkinson's disease; Pramipexole; Primate

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CARBIDOPA; LEVODOPA; PRAMIPEXOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DYSKINESIA; FEMALE; LOCOMOTION; MALE; MARMOSET; MONOTHERAPY; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

ANIMALS; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; CALLITHRIX; CARBIDOPA; DISABILITY EVALUATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DYSKINESIAS; LEVODOPA; MALE; MOTOR ACTIVITY; MPTP POISONING; TIME FACTORS;

EID: 77649092919     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22960     Document Type: Article

References (41)

1. Schapira AH, Emre M, Jenner P, Poewe W. Levodopa in the treatment of Parkinson's disease. Eur J Neurol 2009;16:982-989.
2. Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol Sci 2001;22:93-94.
3. Rascol O. The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease. J Neurol 2000;247 Suppl 2:II51-II57.
4. Radad K, Gille G, Rausch WD. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacol Rep 2005;57:701-712.
5. Schapira AH. Present and future drug treatment for Parkinson's disease. J Neurol Neurosurg Psychiatry 2005;76:1472-1478.
6. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 2005;20 Suppl 11:S11-S16.
7. Stocchi F, Tagliati M, Olanow CW. Treatment of levodopainduced motor complications. Mov Disord 2008;23 Suppl 3: S599-S612.
8. Rinne UK. Treatment of Parkinson's disease: problems with a progressing disease. J Neural Transm 1981;51:161-174.
9. Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs. levodopa in early Parkinson disease. Arch Neurol 2009;66:563-570.
10. Hobson DE, Pourcher E, Martin WR. Ropinirole and pramipexole, the new agonists. Can J Neurol Sci 1999;26 Suppl 2:S27-S33.
11. Obeso JA, Luquin MR, Vaamonde J, Grandas F, Martinez Lage JM. Continuous dopaminergic stimulation in Parkinson's disease. Can J Neurol Sci 1987;14:488-492.
12. Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov Disord 2006;21:343-353.
13. Hubble JP. Long-term studies of dopamine agonists. Neurology 2002;58:S42-S50.
14. Montastruc JL, Rascol O, Senard JM. Treatment of Parkinson's disease should begin with a dopamine agonist. Mov Disord 1999;14:725-730.
15. Smith LA, Jackson MG, Bonhomme C, Chezaubernard C, Pearce RK, Jenner P. Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset. Clin Neuropharmacol 2000;23:133-142.
16. Jackson MJ, Smith LA, Al-Barghouthy G, Rose S, Jenner P. Decreased expression of L-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets. Exp Neurol 2007;204:162-170.
17. Diamond SG, Markham CH. One-year trial of pergolide as an adjunct to Sinemet in treatment of Parkinson's disease. Adv Neurol 1984;40:537-539.
18. Bonuccelli U, Colzi A, Del DP. Pergolide in the treatment of patients with early and advanced Parkinson's disease. Clin Neuropharmacol 2002;25:1-10.
19. Rudzinska M, Szczudlik A. [Apomorphine in off state - clinical experience]. Neurol Neurochir Pol 2007;41:S40-S48.
20. Zaleska B, Domzal T. [Apomorphine in treatment of Parkinson's disease with fluctuations]. Neurol Neurochir Pol 1999;33:1297-1303.
21. Albani C, Zangger I, Fischer G. [Subcutaneous apomorphine infusion in the treatment of Parkinson disease]. Schweiz Rundsch Med Prax 1992;81:1011-1015.
22. Smith LA, Jackson MJ, Johnston L, et al. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates. Clin Neuropharmacol 2006;29:112-125.
23. Stockwell KA, Virley DJ, Perren M, et al. Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets. Exp Neurol 2008;211:172-179.
24. Catalan-Alonso MJ, Del VJ. [Dopaminomimetic psychosis in Parkinson's disease: first symptom of early dementia?] Rev Neurol 2001;32:1085-1087.
25. Melamed E, Friedberg G, Zoldan J. Psychosis: impact on the patient and family. Neurology 1999;52:S14-S16.
26. Pfeiffer R. Optimization of levodopa therapy. Neurology 1992; 42:39-43.
27. Jackson MJ, Al-Barghouthy G, Pearce RK, Smith L, Hagan JJ, Jenner P. Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets. Pharmacol Biochem Behav 2004;79: 391-400.
28. Smith L, De Salvia M, Jenner P, Marsden CD. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated common marmosets. Mov Disord 1996;11:125-135.
29. Jackson MJ, Smith LA, Al-Barghouthy G, Rose S, Jenner P. Decreased expression of L-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets. Exp Neurol 2007;204:162-170.
30. Jackson MJ, Al-Barghouthy G, Pearce RK, Smith L, Hagan JJ, Jenner P. Effect of 5-HT(1B/D) receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets. Pharmacol Biochem Behav 2004;79: 391-400.
31. Smith LA, Jackson MG, Bonhomme C, Chezaubernard C, Pearce RK, Jenner P. Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset. Clin Neuropharmacol 2000;23:133-142.
32. Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov Disord 1995;10:731-740.
33. Barone P. Clinical strategies to prevent and delay motor complications. Neurology 2003;61:S12-S16.
34. Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998;55 Suppl 1:1-9.
35. Jenner P. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann Neurol 2000;47:S90-S99.
36. Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24:1468-1474.
37. Jenner P. Dopamine agonists in Parkinson's disease-focus on non-motor symptoms. Eur J Neurol 2008;15Suppl 2:1.
38. Bittkau S, Przuntek H. Chronic s.c. lisuride in Parkinson's disease-motor-performance and avoidance of psychiatric side effects. J Neural Transm Suppl 1988;27:35-54.
39. Baronti F, Mouradian MM, Davis TL, et al. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Ann Neurol 1992;32:776-781.
40. Obeso JA, Martinez-Lage JM, Luquin MR, Bolio N. Intravenous lisuride infusion for Parkinson's disease. Ann Neurol 1983;14: 252.
41. Facca A, Sanchez-Ramos J. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias. Mov Disord 1996;11:327-329.